Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
NCT ID: NCT00316420
Last Updated: 2010-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2003-12-31
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer
NCT00030732
Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00032175
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
NCT00372944
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
NCT00320749
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
NCT01663272
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capecitabine (Xeloda)
650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
Gemcitabine
750 mg/m2 IV Days 1 \& 8 q 21 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No prior chemotherapy except radiation-sensitizing doses of 5-FU
* No radiotherapy less than 4 weeks prior to the start of the study
Exclusion Criteria
* Moderate to severe renal impairment
* Uncontrolled diabetes
* Inability to swallow tablets
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roche Pharma AG
INDUSTRY
Swedish Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Swedish Medical Center, Swedish Cancer Insitute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip Gold, MD
Role: PRINCIPAL_INVESTIGATOR
Swedish Medical Center Cancer Institute
Henry Kaplan, MD
Role: PRINCIPAL_INVESTIGATOR
Swedish Medical Center Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Swedish Medical Center Cancer Institute
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TI027 PG/HK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.